{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T21:00:28.472361+00:00","company":{"ticker":"INGN","cik":1294133,"company_name":"Inogen Inc"},"pagination":{"limit":100,"returned":12,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"8042e6325c9d04074a50aadd32b7b789a5352282","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"GAAP net loss for the first quarter of 2026 was $8.3 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$85.1 million"},"claim":"Inogen Inc reported first quarter ended March 31, 2026 results: revenue $85.1 million, net income GAAP net loss for the first quarter of 2026 was $8.3 million. Guidance reaffirmed.","evidence_excerpt":"total revenue in the first quarter of 2026 was $85.1 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001294133-26-000014","anchor_url":"https://secwatch.observer/filing/0001294133-26-000014#claim-8042e6325c9d04074a50aadd32b7b789a5352282","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000129413326000014/0001294133-26-000014-index.htm"},{"fact_type":"material_agreement","fact_key":"f8bbd7c030cac9411eb660927f50d8e0fc73180d","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2026-04-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Cooperation Agreement","agreement_type":"other","counterparty":"Kent Lake Partners LP, Kent Lake PR LLC and Benjamin Natter","effective_date":"2026-04-06","item_codes_triggered":["1.01"],"value_text":null},"claim":"Inogen Inc entered into Cooperation Agreement with Kent Lake Partners LP, Kent Lake PR LLC and Benjamin Natter (effective 2026-04-06).","evidence_excerpt":"On April 6, 2026, the Company entered into a Cooperation Agreement (the “Cooperation Agreement”) with Kent Lake Partners LP (“Kent Lake”), Kent Lake PR LLC (“Kent Lake PR”) and Benjamin Natter","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-143703","anchor_url":"https://secwatch.observer/filing/0001193125-26-143703#claim-f8bbd7c030cac9411eb660927f50d8e0fc73180d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000119312526143703/0001193125-26-143703-index.htm"},{"fact_type":"executive_change","fact_key":"4f52cb84d7","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2025-02-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mira Kirti Sahney was appointed as Director at Inogen Inc.","evidence_excerpt":"On January 31, 2025, the Board, upon recommendation of the Nominating and Governance Committee, appointed Mira Kirti Sahney to the Board, effective January 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-012334","anchor_url":"https://secwatch.observer/filing/0000950170-25-012334#claim-4f52cb84d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017025012334/0000950170-25-012334-index.htm"},{"fact_type":"executive_change","fact_key":"fb235d1f0b","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2025-02-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-01-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Thomas A. West resigned as Director at Inogen Inc.","evidence_excerpt":"On January 30, 2025, Thomas A. West notified Inogen, Inc. (“the Company”) of his resignation as a member of the Board of Directors (the “Board”) of the Company, the Compliance Committee of the Board (the “Compliance Committee”), and the Nominating and Governance Committee of the Board (the “Nominating and Governance Committee”), in each case effective as of January 30, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-012334","anchor_url":"https://secwatch.observer/filing/0000950170-25-012334#claim-fb235d1f0b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017025012334/0000950170-25-012334-index.htm"},{"fact_type":"executive_change","fact_key":"d61726acca","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2024-07-31T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-19","interim":false,"role":"Executive Vice President, General Counsel and Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Jason Somer departed as Executive Vice President, General Counsel and Secretary at Inogen Inc.","evidence_excerpt":"the Company and Jason Somer, Executive Vice President, General Counsel and Secretary of the Company, mutually determined that Mr. Somer would separate from the Company on July 19, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-088682","anchor_url":"https://secwatch.observer/filing/0000950170-24-088682#claim-d61726acca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024088682/0000950170-24-088682-index.htm"},{"fact_type":"executive_change","fact_key":"0da0456b4f","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2024-07-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-22","interim":false,"role":"Executive Vice President, Business Development, General Counsel and Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Kevin P. Smith was appointed as Executive Vice President, Business Development, General Counsel and Secretary at Inogen Inc.","evidence_excerpt":"On May 6, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Kevin P. Smith to serve as Executive Vice President, Business Development, General Counsel and Secretary of the Company, effective July 22, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-081526","anchor_url":"https://secwatch.observer/filing/0000950170-24-081526#claim-0da0456b4f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024081526/0000950170-24-081526-index.htm"},{"fact_type":"executive_change","fact_key":"4340abe421","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2024-07-03T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-19","interim":false,"role":"Executive Vice President, General Counsel and Secretary","role_category":"general_counsel","successor_name":"Kevin P. Smith","successor_named":true},"claim":"Jason Somer departed as Executive Vice President, General Counsel and Secretary at Inogen Inc.","evidence_excerpt":"On July 2, 2024, Inogen, Inc. (the “Company”) and Jason Somer, Executive Vice President, General Counsel and Secretary of the Company, mutually determined that Mr. Somer would separate from the Company on July 19, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-081526","anchor_url":"https://secwatch.observer/filing/0000950170-24-081526#claim-4340abe421","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024081526/0000950170-24-081526-index.htm"},{"fact_type":"executive_change","fact_key":"f843f5c293","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2024-05-15T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2024-04-11","interim":false,"role":"Executive Vice President, R&D and Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.","evidence_excerpt":"Dr. Glezer’s role as an officer and employee of the Company ended effective April 11, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-060589","anchor_url":"https://secwatch.observer/filing/0000950170-24-060589#claim-f843f5c293","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024060589/0000950170-24-060589-index.htm"},{"fact_type":"earnings_release","fact_key":"401aaa866fecfbebee3f37179b21c5f5bbeab331","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$14.6 million","period_text":"quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$78.0 million"},"claim":"Inogen Inc reported quarter ended March 31, 2024 results: revenue $78.0 million, net income $14.6 million.","evidence_excerpt":"while strengthening our market leading position. I am excited for the future of Inogen.” First Quarter 2024 Financial Results First quarter total revenue increased 8.1% to $78.0 million from $72.2 million in the first quarter of 2023, primarily driven by higher international and domestic business-to business sales, partially offset by lower direct-to-consumer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-054483","anchor_url":"https://secwatch.observer/filing/0000950170-24-054483#claim-401aaa866fecfbebee3f37179b21c5f5bbeab331","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024054483/0000950170-24-054483-index.htm"},{"fact_type":"executive_change","fact_key":"ad647523fe","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2024-04-15T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-03","interim":false,"role":"Executive Vice President, R&D and Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.","evidence_excerpt":"On April 11, 2024, Inogen, Inc. (the “Company”) and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-044416","anchor_url":"https://secwatch.observer/filing/0000950170-24-044416#claim-ad647523fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/0000950170-24-044416-index.htm"},{"fact_type":"earnings_release","fact_key":"d811288105fa99217d8daa76d475e283b33d7346","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2024-02-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"GAAP net loss for the fourth quarter of 2023 was $26.6 million compared to GAAP net loss of $56.6 million in the fourth","period_text":"the fourth quarter and the full year ended December 31, 2023","report_date":"2024-02-27","result_type":"reported_results","revenue_text":"$75.9 million; full-year 2023 revenue of $315.7 million"},"claim":"Inogen Inc reported the fourth quarter and the full year ended December 31, 2023 results: revenue $75.9 million; full-year 2023 revenue of $315.7 million, net income GAAP net loss for the fourth quarter of 2023 was $26.6 million compared to GAAP net loss of $56.6 million in the fourth.","evidence_excerpt":"Inogen Announces Fourth Quarter and Full-Year 2023 Financial Results Fourth quarter 2023 revenue of $75.9 million; full-year 2023 revenue of $315.7 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-021113","anchor_url":"https://secwatch.observer/filing/0000950170-24-021113#claim-d811288105fa99217d8daa76d475e283b33d7346","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024021113/0000950170-24-021113-index.htm"},{"fact_type":"executive_change","fact_key":"181e9e006e","cik":1294133,"ticker":"INGN","company_name":"Inogen Inc","filed_at":"2024-01-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-04","interim":false,"role":"Executive Vice President, Chief Financial Officer and Treasurer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Michael Bourque was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Inogen Inc.","evidence_excerpt":"On January 21, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Michael Bourque to serve as Executive Vice President, Chief Financial Officer and Treasurer (“CFO”) of the Company, effective March 4, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-006969","anchor_url":"https://secwatch.observer/filing/0000950170-24-006969#claim-181e9e006e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024006969/0000950170-24-006969-index.htm"}]}